NasdaqCM - Delayed Quote • USD
Greenwich LifeSciences, Inc. (GLSI)
At close: April 24 at 4:00 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Snehal S. Patel | CEO, CFO & Director | 1.09M | -- | 1964 |
Mr. Eric Rothe | Founder & Independent Director | 65.64k | -- | 1976 |
Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer & Director | -- | -- | 1951 |
Dr. Jaye L. Thompson Ph.D. | Vice President Clinical & Regulatory Affairs | -- | -- | 1966 |
Dr. Christine T. Fischette Ph.D. | VP of Business Development | -- | -- | 1951 |
Greenwich LifeSciences, Inc.
Building 14
3992 Bluebonnet Drive
Stafford, TX 77477
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 3
Description
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Corporate Governance
Greenwich LifeSciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 15, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 20, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 14, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Dec 15, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Oct 25, 2023DEFA14A: Proxy StatementsSee Full Filing
Upcoming Events
May 22, 2024 - May 27, 2024
Greenwich LifeSciences, Inc. Earnings Call
Related Tickers
SLS SELLAS Life Sciences Group, Inc.
1.5400
-5.52%
IMMP Immutep Limited
2.5900
+3.19%
VERU Veru Inc.
1.3200
+3.53%
ANVS Annovis Bio, Inc.
12.74
+7.24%
GANX Gain Therapeutics, Inc.
3.1900
-5.90%
EFTR eFFECTOR Therapeutics, Inc.
1.8500
-4.64%
CALC CalciMedica, Inc.
5.49
+19.87%
OTLK Outlook Therapeutics, Inc.
8.20
0.00%
XBIO Xenetic Biosciences, Inc.
3.8400
-0.26%
ANRO Alto Neuroscience, Inc.
14.20
+2.31%